CDK5 and Alzheimer disease: After 18 weeks of DPIN treatment, significant reductions in Aβ deposits, phosphorylated tau, and the P35/CDK5 ratio were observed in 5×FAD mice, suggesting DPIN’s potential in addressing critical neuropathological features of AD.